Global Orphan Drugs Rare Disease Therapy Market Opportunity Estimated At USD 350 Billion By 2021 Says Kuick Research
Global Orphan Drugs Rare Disease Therapy Market Opportunity Estimated At USD 350 Billion By 2021 Says Kuick Research
Global Orphan Drugs Market & Clinical Trials Insight Report 2028 Highlights:
- Clinical Insight On More Than 600 Marketed Orphan Drugs
- Clinical Insight On More Than 1300 Orphan Drugs in Clinical Trials
- Orphan Designated Drug Clinical Status by Indication & Country
- Global Market Opportunity More Than USD 350 Billion
- Market Exclusivity & Patent Protection Criteria for Orphan Drugs
- Global & Regional Orphan Drug Market Sales Opportunity
- Orphan Drug Reimbursement Policy
- Orphan Clinical Pipeline Overview Company, Drug Class, Formulation, Indication, Region, Priority Status, Patient Segment, Phase
Download Report Sample:
https://www.kuickresearch.com/ccformF.php?t=1643976472
Orphan drugs refer to the pharmaceuticals which are used for the diagnosis, prevention, and treatment of rare medical disorders. Rare diseases are a health condition which generally affects small number of people compared with other prevalent diseases in general population. It is estimated that globally around 6000-8000 rare diseases exist with new rare diseases being reported in medical literature regularly. As rare diseases have low prevalence and individually rare, collectively they affect around 6-8% of the population. These diseases include genetic disorders, rare cancers, infectious topical diseases, and degenerative diseases. Around 80% of the rare diseases are genetic in nature and therefore mainly affects children.
The last few years have seen rapid influx in approval of orphan drugs which is mainly attributed to the restless efforts by scientists and rising awareness among population. Several orphan drugs including Imbruvica, Revlimid, Trikafta, Hemlibra, and others have shown robust response in the market. The top selling orphan drugs in the market are mentioned in table below.
Presently, oncology orphan drugs occupy the majority of share in the market. Almost 200 rare cancers have been identified which all together represent 22% of all cancer incidences. It has been suggested that except for 5 major tumors including breast, lung, colorectal, prostate, and bladder cancers, all others are classified as rare. Moreover, the advancements in the science and technology and better understanding of cancer has allowed further segmentation of cancer types in smaller subgroups.
Key Orphan Drug Sales 2021:
| Drug | Company | FDA Approval | Indication | 2021 Sales |
| Keytruda | Merck | 2014 | melanoma, NSCLC, HNSCC, classical HL, primary mediastinal large B-cell lymphoma, urothelial carcinoma, CRC, gastric cancer, esophageal cancer, cervical cancer, hepatocellular carcinoma, Merkel cell carcinoma, renal cell carcinoma, endometrial carcinoma, tumor mutational burden-high (TMB-H) cancer, cutaneous squamous cell carcinoma, and TNBC. | US$ 17.18 Billion |
| Revlimid | Bristo Myers Squibb | 2005 | Multiple myeloma, Follicular Lymphoma, myelodysplastic syndromes, mantle cell lymphoma, marginal zonal lymphoma | US$ 12.8 Billion |
| Opdivo | Bristo Myers Squibb | 2014 | NSCLC, malignant pleural mesothelioma, renal cell carcinoma, classical Hodgkin lymphoma, HNSCC, urothelial carcinoma, CRC, hepatocellular carcinoma, esophageal cancer, gastric cancer, and gastroesophageal junction cancer. | US$ 7.52 Billion |
| Trikafta | Vertex Pharmaceutical | 2019 | Cystic Fibrosis | US$ 5.69 Billion |
| Imbruvica | AbbVie | 2015 | Mantle Cell Lymphoma; Chronic Lymphocytic Leukemia; Waldenström’s Macroglobulinemia; Small Lymphocytic Lymphoma; Marginal Zone Lymphoma | US$ 5.4 Billion |
| Hemlibra | Genentech | 2017 | Hemophilia A | US$ 2.35 Billion |
| Lynparza | AstraZeneca | 2014 | Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer | US$ 2 Billion |
| Vyndaqel | Pfizer | 2019 | Cardiomyopathy of Transthyretin-Mediated Amyloidosis | US$ 2 Billion |
| Darzalex | Janssen Biotech | 2015 | Multiple Myeloma | US$ 1.64 Billion |
| Soliris | Alexion Pharmaceuticals
| 2007 | Paroxysmal Nocturnal Hemoglobinuria, Hemolytic Uremic Syndrome, Myasthenia Gravis | US$ 1 Billion |
| Venclexta | Abbvie | 2016 | Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia | US$ 934 Million |
| Jakafi | Incyte Corporation | 2011 | Myelofibrosis | US$ 592 Million |
For More Information Related To Report Contact:
Neeraj Chawla
Research Head
Kuick Research
+919810410366